Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-04-07Clinical Trial Update: Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma [Phase 2]
Phase 2 clinical trial evaluating the combination of ibrutinib with methotrexate and temozolomide for newly diagnosed primary central nervou…
-
CLINICAL_TRIALS trial_result · 2022-04-05Clinical Trial Update: Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial update for a CAR-T therapy targeting Igβ in relapsed/refractory B-cell non-Hodgkin's lymphoma.
-
CLINICAL_TRIALS trial_result · 2022-04-04Clinical Trial Update: Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
Clinical trial update for ONC201 in relapsed/refractory non-Hodgkin's lymphoma, including phase 1 and phase 2 cohorts; study status terminat…
-
CLINICAL_TRIALS trial_result · 2022-03-31Clinical Trial Update: Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study [Phase 4]
Phase 4 clinical trial update for Ultrafast Truxima infusion in Non-Hodgkin's Lymphoma (Txagorapid Study).
-
CLINICAL_TRIALS trial_result · 2022-03-31Clinical Trial Update: GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma [Phase 2]
Phase 2 trial update for GOAL: GA101 plus pixantrone in relapsed aggressive lymphoma (non-Hodgkin lymphoma).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-03-11Clinical Trial Update: A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma [Phase 2]
Phase II study evaluating zanubrutinib with lenalidomide and R-CHOP as first-line therapy for diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2022-03-10Clinical Trial Update: A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer [Phase 1, Phase 2]
Phase 1/2 trial of SRA737 in advanced solid tumors and non-Hodgkin's lymphoma has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2022-03-09Clinical Trial Update: Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
Phase 1/2 study evaluating chimauranib in combination with chidamide for relapsed/refractory non-Hodgkin's lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2022-02-18Clinical Trial Update: A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma [Phase 1]
Phase 1 study of TAK-659 in combination with various agents for advanced non-Hodgkin lymphoma was terminated; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-02-17Clinical Trial Update: An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma [Phase 1, Phase 2]
This clinical trial update reports on the safety and effectiveness of combining Nivolumab and Daratumumab in patients with multiple myeloma …
-
CLINICAL_TRIALS trial_result · 2022-02-15Clinical Trial Update: T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma [Phase 1]
Phase 1 trial evaluating T cells engineered with fully-human anti-CD19 and anti-CD20 CARs for B-cell malignancies and Hodgkin lymphoma; the …
-
CLINICAL_TRIALS trial_result · 2022-01-27Clinical Trial Update: A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) [Phase 1, Phase 2]
Phase I/II study investigating CM355 in relapsed or refractory B-cell non-Hodgkin's lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-12-21Clinical Trial Update: Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A phase 1/2 clinical trial investigates a genetically engineered lymphocyte therapy given after peripheral blood stem cell transplant in pat…
-
CLINICAL_TRIALS trial_result · 2021-12-03Clinical Trial Update: Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating allogeneic CD19 CAR-T cells for relapsed/refractory B-cell lymphoma including non-Hodgkin lymphoma.
-
FDA approval · 2021-12-02FDA Approved: RITUXAN — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Rituxan (rituximab) filed by Genentech, Inc., resulting in updated labeling for the product.
-
CLINICAL_TRIALS trial_result · 2021-11-05Clinical Trial Update: Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating pralatrexate for relapsed or refractory B-cell non-Hodgkin's lymphoma has completed, with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-11-03Clinical Trial Update: A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma [Phase 3]
A Phase III randomized trial comparing low-dose versus standard-dose mBACOD chemotherapy with rGM-CSF for AIDS-associated non-Hodgkin lympho…
-
FDA approval · 2021-10-25FDA Approved: METHOTREXATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Methotrexate by Hikma Pharmaceuticals USA Inc. (ANDA089342).
-
CLINICAL_TRIALS trial_result · 2021-10-04Clinical Trial Update: Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 study comparing Zevalin alone versus Zevalin with motexafin gadolinium in rituximab-refractory low-grade or follicular B-cell non-Ho…
-
CLINICAL_TRIALS trial_result · 2021-10-04Clinical Trial Update: Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT [Phase 1, Phase 2]
Clinical trial update on ex-vivo primed memory donor lymphocyte infusion to boost antiviral immunity after T-cell depleted hematopoietic ste…
-
CLINICAL_TRIALS trial_result · 2021-09-30Clinical Trial Update: Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies [Phase 1, Phase 2]
Clinical trial update on combining acalabrutinib (ACP-196) with ACP-319 for B-cell malignancies, including non-Hodgkin lymphoma, multiple my…
-
CLINICAL_TRIALS trial_result · 2021-09-28Clinical Trial Update: MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study [Phase 1]
Phase 1 study update for MEN1309 intravenous infusion in CD205-positive metastatic solid tumors and relapsed/refractory non-Hodgkin lymphoma…
-
CLINICAL_TRIALS trial_result · 2021-09-21Clinical Trial Update: Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
Clinical trial update for AMG 531 evaluating safety and efficacy in patients with Non-Hodgkin's Lymphoma across Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2021-09-14Clinical Trial Update: A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL) [Phase 1]
Phase 1 trial of TAK-659 as a single agent in adult East Asian participants with various non-Hodgkin lymphoma subtypes was terminated.
-
CLINICAL_TRIALS trial_result · 2021-08-26Clinical Trial Update: Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma [Phase 1, Phase 2]
Clinical trial evaluating orelabrutinib in combination with thiotepa for refractory and relapsed primary CNS lymphoma (PCNSL) across Phase 1…